Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Sepiapterin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PTC Therapeutics' NDA for Sepiapterin Accepted for Phenylketonuria
    PTC Therapeutics' NDA for Sepiapterin Accepted for Phenylketonuria

    01 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-sepiapterin-for-the-treatment-of-pediatric-and-adult-phenylketonuria-patients-302263975.html

    PR NEWSWIRE
    01 Oct 2024
    Share Share
    PTC Therapeutics Reports Q2 2024 Results And Corporate Update
    PTC Therapeutics Reports Q2 2024 Results And Corporate Update

    08 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial-results-302218200.html

    PR NEWSWIRE
    08 Aug 2024
    Share Share
    PTC Therapeutics Announces Validation of Sepiapterin European MAA
    PTC Therapeutics Announces Validation of Sepiapterin European MAA

    28 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-validation-of-sepiapterin-european-maa-302156304.html

    PR NEWSWIRE
    28 May 2024
    Share Share
    PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
    PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

    28 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-announces-submission-of-sepiapterin-maa-for-treatment-of-pku-to-ema-302102471.html

    PR NEWSWIRE
    28 Mar 2024
    Share Share
    PTC Therapeutics Announces Presentation on PKU and Sepiapterin
    PTC Therapeutics Announces Presentation on PKU and Sepiapterin

    11 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-virtual-presentation-on-phenylketonuria-pku-and-sepiapterin-301874444.html

    PR NEWSWIRE
    11 Jul 2023
    Share Share
    PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
    PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals

    01 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-successfully-completes-acquisition-of-censa-pharmaceuticals-301068302.html

    PRNEWSWIRE
    01 Jun 2020
    Share Share